




F




G






H




I





J




K




Non-Denaturing Conditions







G




A




B




C




H




D




E









F





I



G







A

PEO1


500nM cisplatin: Untreated




24h




48h



72h



120h




Annexin V (RFU)


B

C4-2


500nM cisplatin: Untreated




24h




48h










72h





120h







Annexin V (RFU)



G



H



Cell line	HR	FP	GS	Cisplatin Response
BRCA1/2 proficient	+	+	+	Resistant
BRCA2 and CHD4 deficient	-	+	+	Resistant
BRCA2 S3291A mutant	+	-	+	Resistant
BRCA1/2 deficient	-	-	-	Hypersensitive
RAD51 T131P mutant	+	-	-	Hypersensitive
RAD51 T131P mutant and RADX deficient	+	+	-	Hypersensitive
BRCA2 deficient and MRE11 inhibited	-	+	-	Hypersensitive
BRCA2 and SMARCAL1 deficient	-	+	-	Hypersensitive
